Hypersomnia Whole Blood

Hypersomnia Whole Blood for Sleep-Wake and Neurological Research

Hypersomnia Whole Blood is collected from IRB-consented donors with a clinically confirmed hypersomnia diagnosis and shipped same-day to preserve cell viability and RNA integrity. Hypersomnia encompasses the central disorders of hypersomnolence, characterised by excessive daytime sleepiness despite adequate or prolonged nocturnal sleep. These are sleep-wake regulatory disorders; no established autoimmune mechanism underlies idiopathic hypersomnia or narcolepsy type 2, and this product is not positioned as an autoimmune specimen.

Sleep-Wake Biology and Why Whole Blood

• The central disorders of hypersomnolence include idiopathic hypersomnia, narcolepsy type 2, and Kleine-Levin syndrome. Their shared clinical feature is pathological excessive daytime somnolence, and for idiopathic hypersomnia and narcolepsy type 2 the underlying pathophysiology remains unresolved.
• Diagnosis rests on objective measurement rather than symptom report: overnight polysomnography to exclude other causes, the multiple sleep latency test (MSLT) to quantify mean sleep latency and sleep-onset REM periods, and actigraphy or extended monitoring to document total sleep time.
• Idiopathic hypersomnia is often accompanied by prolonged sleep time and severe sleep inertia, and unlike narcolepsy type 1 it is not defined by cataplexy or by a deficiency of a known neuropeptide.
• Narcolepsy type 1 is a mechanistically distinct entity involving loss of hypothalamic hypocretin (orexin) neurons and a strong HLA-DQB1*06:02 association. An immune-mediated basis has been proposed but remains unproven, and that hypothesis does not extend to idiopathic hypersomnia or narcolepsy type 2.
• Sleep-wake regulation involves monoaminergic, histaminergic, adenosinergic, and GABAergic signalling together with circadian clock gene output, which is why wake-promoting agents acting on dopamine reuptake, histamine H3 receptors, and GABA-B signalling are the mainstay of symptomatic treatment.
• Whole blood preserves leukocytes and the plasma compartment together, supporting circadian and clock gene expression analysis, HLA and pharmacogenomic genotyping, and DNA and RNA extraction from a single specimen.

Donor Stratification Available

• Diagnostic subtype: idiopathic hypersomnia, narcolepsy type 2, or other central disorder of hypersomnolence
• Objective sleep measures where documented: MSLT mean sleep latency, number of sleep-onset REM periods, and polysomnography findings
• Documented long sleep time, actigraphy results, and presence of severe sleep inertia
• Subjective sleepiness severity, including Epworth Sleepiness Scale score where recorded
• Treatment status: untreated versus wake-promoting agent treated, including modafinil, solriamfetol, pitolisant, or oxybate
• Exclusion or documentation of comorbid obstructive sleep apnoea, insufficient sleep, shift work, and psychiatric comorbidity; collection time of day available on request
• Matched healthy controls available

Product Features

• Fresh whole blood from clinically diagnosed hypersomnia donors
• Custom anticoagulants and collection tubes available, including RNA-stabilising tubes
• Same-day collection and shipment
• Standard and custom volumes
• IRB-approved protocols and electronic informed consent
• Research Use Only (RUO)

De-identified Donor Data

• Physician-confirmed diagnosis, including sleep study results where available
• Demographics: age, sex assigned at birth, ethnicity
• Relevant medical and treatment history
• Diagnostic subtype and objective sleep measures where documented
• Additional hypersomnia-specific metadata available on request

Applications

• Circadian and clock gene expression analysis in stabilised whole blood
• Whole-blood transcriptomic profiling of donors stratified by objective sleepiness measures
• DNA extraction for HLA typing and candidate-gene or genome-wide association work
• Pharmacogenomic research on wake-promoting agent metabolism and response
• Neurochemical, hormonal, and metabolic profiling in the paired plasma fraction, including cortisol and melatonin-pathway analytes
• Immunophenotyping of circulating leukocyte subsets for exploratory characterisation
• Biomarker discovery to support objective differentiation of hypersomnolence subtypes
• Assay development and reference-range establishment for sleep medicine research panels

Other Hypersomnia Specimen Types

• Hypersomnia Plasma
• Hypersomnia Serum
• Hypersomnia PBMC

Looking for narcolepsy specifically? See our Narcolepsy Whole Blood product.

Compliance and Quality Assurance

• IRB-approved protocols and electronic informed consent
• 21 CFR Part 11-compliant e-consent
• HIPAA-compliant donor data handling

Ordering & Customization

Hypersomnia whole blood is available in standard and custom volumes. For pricing, international orders, or documentation requirements, email learnmore@sanguinebio.com. To compare donor availability across conditions, visit our human whole blood page.